Stephen A. Sherwin Sells 8,760 Shares of Biogen Inc. (NASDAQ:BIIB) Stock

Biogen Inc. (NASDAQ:BIIB) Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Biogen Stock Up 0.2 %

Shares of BIIB traded up $0.33 during trading on Monday, reaching $150.71. The company’s stock had a trading volume of 2,598,400 shares, compared to its average volume of 1,543,039. Biogen Inc. has a twelve month low of $128.51 and a twelve month high of $238.00. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The company has a market cap of $22.06 billion, a price-to-earnings ratio of 13.47, a P/E/G ratio of 1.51 and a beta of 0.01. The company has a fifty day moving average of $143.98 and a two-hundred day moving average of $166.18.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. On average, sell-side analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Biogen

Large investors have recently added to or reduced their stakes in the company. Lee Danner & Bass Inc. bought a new stake in Biogen during the fourth quarter valued at $25,000. Larson Financial Group LLC grew its position in shares of Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 141 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in Biogen during the third quarter worth about $33,000. Colonial Trust Co SC raised its stake in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 186 shares during the period. Finally, SRS Capital Advisors Inc. bought a new position in Biogen in the fourth quarter worth about $33,000. 87.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on BIIB shares. Scotiabank lowered their price objective on Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a research report on Thursday, February 13th. Morgan Stanley cut their price objective on shares of Biogen from $192.00 to $157.00 and set an “equal weight” rating on the stock in a report on Thursday, February 13th. Citigroup lowered their target price on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Wolfe Research started coverage on shares of Biogen in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Finally, Mizuho lowered their price objective on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Seventeen research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $213.33.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.